Globe Biotech Limited (GBL) has completed the preclinical or animal trials of its homegrown coronavirus vaccine 'Bangavax' on Thursday.
The GBL conducted the trial on monkeys to meet the condition set by Bangladesh Medical Research Council (BMRC). The trial was completed on October 21.
“During the animal trial of the Bangavax vaccine on monkeys, we have found that it has created sufficient anti-body and hundred per cent effective against all 11 coronavirus variants including the Delta one,” a senior manager of Globe Biotech Limited Dr Mohammad Mohiuddin told the Daily Sun.
Based on the successful trials, company officials said, the local drug firm had approached the BMRC for ethical clearance before the human trials.
But the council approved clinical trials of Bangavax under the condition that "before starting any human trial, the vaccine producer will require to conduct an animal trial on monkeys or chimpanzees. Later, the GBL started animal trials of Bangavax on monkeys on August 1st in line with BMRC's condition, the company sources said.
They will now submit their clinical trial protocol to the BMRC next week to get approval for carrying out the human trial, they said. The company is planning to conduct the human trials from November.
Bangavax sought ethical approval from the BMRC for human trials of the antidotes on January 17 this year.
Bangladeshi company Globe Biotech has received approval from the Directorate General of Drug Administration (DGDA) for manufacturing its vaccine for a clinical trial. The company was granted permission on 28 December last year, sources said.